Core Insights - Silexion Therapeutics has completed the data collection phase for its first evaluation of SIL-204 in clinically relevant orthotopic pancreatic cancer models, marking a significant milestone in its development program [1][2][3] Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, with its first-generation product, LODER™, showing promising results in Phase 2 trials for non-resectable pancreatic cancer [4] - The company is advancing its next-generation siRNA candidate, SIL-204, which targets a broader range of KRAS mutations [4] Study Details - The study evaluated SIL-204's ability to reduce primary tumor growth and metastatic spread in orthotopic pancreatic cancer models, which better reflect human pancreatic cancer biology compared to traditional subcutaneous xenograft models [2][6] - The orthotopic models allow for a more accurate assessment of tumor behavior and therapeutic efficacy against both primary and metastatic disease [2] Future Expectations - Initial results from the study are expected to be reported in March 2025, which will inform Silexion's development strategy for SIL-204 [3]

Core Viewpoint - Silexion Therapeutics Corp. has entered into agreements for the immediate exercise of warrants to purchase 2,221,523 ordinary shares at an exercise price of $1.35 per share, expecting gross proceeds of approximately $3.3 million, which will be used for working capital and general corporate purposes [1][3]. Group 1: Financial Details - The gross proceeds from the exercise of the warrants are expected to be approximately $3.3 million before deducting fees and expenses [1]. - The company will issue new unregistered warrants to purchase the same number of ordinary shares at an exercise price of $1.50 per share, with a term of twenty-four months [3]. - The additional payment for the new warrants totals $277,690.38, included in the gross proceeds [3]. Group 2: Regulatory and Compliance - The new warrants and the shares issuable upon their exercise are not registered under the Securities Act of 1933 and may not be sold in the U.S. without registration or an exemption [4]. - The company has agreed to file a registration statement with the SEC for the resale of the ordinary shares from the new warrants [4]. Group 3: Company Overview - Silexion Therapeutics is focused on developing RNA interference therapies for KRAS-driven cancers, with its first-generation product, LODER™, showing promise in Phase 2 trials for non-resectable pancreatic cancer [6]. - The company is advancing its next-generation siRNA candidate, SIL-204, which targets a broader range of KRAS mutations and has shown significant potential in preclinical studies [6].

Core Insights - Silexion Therapeutics Corp. announced promising preclinical data for SIL-204, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models, validating systemic administration as an effective delivery method [1][2][5] Preclinical Data Highlights - SIL-204 reduced tumor growth by approximately 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic tumors with a G12D mutation xenografted into mice [7] - A single systemic administration of SIL-204 maintained effective drug levels in rat plasma and tissues for over 56 days [7] - SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D [7] - Intratumoral administration of SIL-204 microparticles reduced tumor cell numbers by approximately 3-fold and increased tumor necrosis by approximately 5-fold after 15 days in human pancreatic cancer xenograft harboring a KRAS G12V mutation in mice [7] Future Development Plans - The company is exploring how the new data can inform an expanded treatment strategy for KRAS-driven cancers and plans to announce details of its expanded development plan shortly [3]

Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, which are the most common oncogenic drivers in human cancers [7] - The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer [7] - Silexion is advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies [7] Public Offering Details - Silexion Therapeutics announced the pricing of a public offering of 3,703,703 ordinary shares (or equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share [5] - The warrants have an exercise price of $1.35 per share, are exercisable immediately upon issuance, and will expire five years from the date of issuance [5] - The gross proceeds from the offering, before deducting fees and expenses, are expected to be approximately $5.0 million [6] - The net proceeds will be used to advance the company's pre-clinical studies and for general corporate purposes [6] Regulatory and Offering Information - The securities are being offered pursuant to a registration statement on Form S-1 (File No. 333-282932), which was declared effective by the SEC on January 15, 2025 [2] - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [6] - The closing of the offering is expected to occur on or about January 17, 2025, subject to customary closing conditions [5]

Core Insights - Silexion Therapeutics Corp. has announced new preclinical results showing the synergistic efficacy of its siRNA candidate SIL-204 in combination with first-line chemotherapy agents for pancreatic cancer, specifically 5-fluorouracil and irinotecan, as well as gemcitabine [2][4] Group 1: Preclinical Results - SIL-204 demonstrates significant synergistic activity with 5-fluorouracil and irinotecan in human pancreatic tumor cell lines with KRAS G12D mutations, which are the most common mutations in pancreatic cancer [2][3] - The combination of SIL-204 with 5-fluorouracil and irinotecan resulted in a significant reduction in cancer cell confluence after approximately three days, with a p-value of less than 0.0005, indicating strong statistical significance [3] Group 2: Clinical Development Plans - Silexion plans to initiate toxicology studies for SIL-204 in the upcoming months and aims to advance it into Phase 2/3 clinical trials in the first half of 2026, focusing on locally advanced pancreatic cancer (LAPC) [5] - The company is also preparing to conduct preclinical studies for SIL-204 in colorectal cancer models [5] Group 3: Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference therapies targeting KRAS mutations, which are prevalent in various cancers [6] - The company's first-generation product, LODER™, has shown promising results in Phase 2 trials for non-resectable pancreatic cancer, indicating a strong foundation for its ongoing research and development efforts [6]

Company Overview - Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotech company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers [1] - The company is pioneering innovative RNAi therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers [4] - Silexion's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer [4] - The company is advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies [4] Upcoming Presentation - Silexion will present a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, California, from January 23-25, 2025 [1] - The presentation will focus on SIL-204 siRNA, both free and encapsulated in extended release microparticles, for the treatment of localized and systemic cancer with specific KRAS mutations (G12x, Q61H, or G13D) [4] - The abstract will be published on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 [3] - The poster will be available on Silexion Therapeutics' website under the "Our Science" section following the presentation [3] Presentation Details - Title: SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation [4] - Presenter: Mitchell Shirvan, Ph.D. [4] - Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract [4] - Abstract Number: 745 [4] - Session Date & Time: January 24, 2025, 11:30 AM-1:00 PM PST [4] Industry Context - The 2025 ASCO Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and provide oncologists with the information needed to deliver high-quality patient care [2]

Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today revealed its ongoing collaboration with Evonik, a global leader in specialty chemicals, for the development of an advanced siRNA formulation aimed at enhancing cancer treatment efficacy. Through this existing collaboration, Evonik's proprietary biodegradable long-acting PLGA (RESOMER®) microparticle ...

GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 27, 2024, and the Company’s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Global Market at market open on November 29 ...

Exhibit 99.1 Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Significant advancements in clinical and preclinical programs targeting KRAS-driven cancers; company advancing pipeline with focus on challenging oncology indications. GRAND CAYMAN, Cayman Islands, November 14, 2024 - Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40073 SILEXION THERAPEUTICS CORP (Exact name of registrant as specified in its charter) | --- | --- | --- | |--------------------- ...